GEMINI II & III Posthoc Analysis Reports Clinical Benefits of Vedolizumab as Induction and Maintenance Therapy in Tumor Necrosis FactorNaive Patients with Moderately to Severely Active Crohn's Disease

Osaka Japan December 9 2016 Takeda Pharmaceutical Company Limited TSE 4502 “Takeda” announced that an analysis based on prespecified and posthoc exploratory outcomes of GEMINI II and GEMINI III data evaluating Entyvio vedolizumab the...